Navigation Links
Heat-shock protein vaccine reduces alveolar bone loss

Heat-shock protein (HSP) can be utilized as a vaccine to cross-protect against multiple pathogenic species. Investigators from Pusan National University (South Korea) today presented the findings of a study they performed to evaluate the bacterium Porphyromonas gingivalis heat-shock protein (HSP) 60 as a vaccine candidate to inhibit multiple bacteria-induced alveolar bone loss.Recombinant P. gingivalis HSP60 was produced and purified from P. gingivalis GroEL gene. Rats were immunized with P. gingivalis HSP60, and experimental alveolar bone loss was induced by infection with multiple periodontopathogenic bacteria.

There was a very strong inverse relationship between post-immune anti-P. gingivalis HSP immunoglobulin G levels and the amount of alveolar bone loss induced by either P. gingivalis or multiple bacterial infection (p = 0.007). Analysis of data from polymerase chain-reaction indicated that the vaccine successfully eradicated the multiple pathogenic species.

The researchers concluded that P. gingivalis HSP60 could potentially be developed as a vaccine to inhibit periodontal disease induced by multiple pathogenic bacteria.


'"/>

Source:International & American Association for Dental Research


Page: 1

Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heat shock protein vaccine reduces alveolar bone loss

(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... MD The Federation of American Societies for ... for the Science Research Conference (SRC): Neural Mechanisms ... Research Conference, Neural Mechanisms in Cardiovascular Regulation, is ... focus on neural mechanisms that regulate normal cardiovascular ...
... Federation of American Societies for Experimental Biology (FASEB) ... Research Conference (SRC): Matricellular Proteins in Development, Health, ... surrounding extracellular matrix (ECM) are the basis for ... organization in all metazoan organisms. Structural ECM components ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Hematologic ... Malignancies is an important and unique scientific conference ... and myeloma is presented in detail in the ...
Cached Biology News:FASEB SRC announces conference: Matricellular Proteins in Development, Health, and Disease 2
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... to design computer chips and electronic circuitry for extreme ... electrical engineers at Vanderbilt University has developed all the ... thin films of nanodiamond. They have created diamond versions ... a key element in computers., "Diamond-based devices have the ...
... Mass., Aug. 4, 2011 Interleukin Genetics, Inc. ... call and Webcast on Friday, August 12 at 9:30 a.m. ... To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 ... will be available on the Investors section of Interleukin Genetics, ...
... N.J., Aug. 4, 2011 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of AZD2820, a ... a single-agent therapy for the treatment of obesity. AZD2820 ... collaborative research program with Palatin Technologies. Obesity ...
Cached Biology Technology:Designing diamond circuits for extreme environments 2Designing diamond circuits for extreme environments 3Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3
Quartz-Halogen, 100 W, High Intensity...
... System with Gateway™ Technology is designed ... the polyhedrin promoter. The expression cassette ... (bacmid DNA) by site-specific transposition (Tn7) ... recombinant bacmid DNA is then used ...
...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
Biology Products: